Novartis Collaborates with Precision Bio in Gene Editing Pact

By Lucy Haggerty

Pharma Deals Review: Vol 2022 Issue 6 (Table of Contents)

Published: 24 Jun-2022

DOI: 10.3833/pdr.v2022.i6.2699     ISSN: 1756-7874

Section: Research & Development



Novartis has entered into an in vivo gene editing collaboration and licensing agreement with Precision Biosciences to develop potentially curative therapies for certain haemoglobinopathies such as sickle cell disease and beta thalassemia...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details